ACC.24: Late-Breaking Science Video Collection

Published: 06 April 2024

  • Views:

    Views Icon 4961
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

Our recurring review series, View from the Thoraxcenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offers a thorough examination of late-breaking and featured scientific findings, highlighting significant data.

 

To delve deeper into the pivotal clinical trial data unveiled at ACC 24, Dr Harriette Van Spall (McMaster University, Hamilton, CA) conducts interviews with the principal investigators as part of her Late-Breaker Discussion Series.

 

For brief and focused coverage of the essential data unveiled, our accessible Expert Interviews were conducted with a select group of faculty members, concentrating on the results, relevance, and implications for future research.

 

Watch our Behind the Heart series to learn more the personal perspectives from the investigators behind top trials in cardiovascular science.

More from this programme

Part 1

View from the Thoraxcenter

In these concise episodes of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offer their thoughts on the top late-breaking trials that will be presented at ACC.24. 

Part 2

Late-Breaker Discussion Series

Part 5

Behind the Heart

Watch our Behind the Heart series to learn more the personal perspectives from the investigators behind top trials in cardiovascular science.

About the episode

ACC.24 — Investigators, Dr Rasha K Al-Lamee and Dr Michael Foley (Imperial College London, UK) joined us to discuss the ORBITA COSMIC trial (NCT04892537).

This randomized, double-blinded, placebo-controlled trial investigated the effects of coronary sinus reducer (CSR) as compared to placebo on myocardial perfusion via MRI, exercise duration, and symptoms in patients with refractory angina and ischemia. Fifty patients with stable coronary artery disease (CAD), ineligible for percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery (CABG), were enrolled in the trial.

Findings demonstrated that CSR showed no improvement in transmural myocardial perfusion, but improved subendocardial perfusion. Findings showed a reduced angina frequency, and improved heart disease related quality of life.

Questions

  1. What is the importance of ORBITA COSMIC?
  2. Could you tell us about the study device?
  3. What was the study design, eligibility criteria, and endpoints?
  4. What are the key results?
  5. Can you share more details about the mechanism of action?
  6. What are the take-home messages?
  7. What are the next steps?

Support: This is an independent interview conducted by Radcliffe Cardiology.

Recorded on-site at ACC.24, Atlanta.

Interviewer: Mirjam Boros
Editor: Jordan Rance
Videographer: Dan Brent, Tom Green, Mike Knight

Faculty Biographies

Michael Foley

View full profile
Rasha Al-Lamee

Rasha Al-Lamee

Interventional Cardiology Consultant

Dr Rasha Al-Lamee is an interventional cardiology consultant at Imperial College Healthcare NHS Trust, London, UK.  

Dr Al-Lamee studied at the University of Oxford and University College London. She completed her training in clinical cardiology on the north-west London cardiology rotation in 2013, and completed her PhD at Imperial College London in 2018.

Dr Al-Lamee’s research interests are complex coronary intervention, coronary physiology and invasive intravascular assessment. She designed, conducted and led the ORBITA trial and is lead author of the primary publication in The Lancet. Dr Al-Lamee has more than 50 peer-reviewed publications and has presented at international cardiology conferences worldwide.  

View full profile

Comments

You must be to comment. If you are not registered, you can register here.